CEPI, the Coalition for Epidemic Preparedness Innovations, yesterday announced a $43.5 million deal with pharmaceutical giant AstraZeneca to advance the development of a novel antibody that could ...
By Chandini Monnappa (Reuters) -Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to ...
As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...
AstraZeneca scrapped a £450m vaccine plant in Liverpool after the UK government missed a critical funding deadline. The ...
AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...
The deal includes the Belgian biotech’s vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...
AstraZeneca is hopping on the pickleball craze for the latest iteration of its Stepping Back Out campaign for asthma ...
(Reuters) -Drugmaker AstraZeneca has agreed to buy biotechnology company EsoBiotec for up to $1 billion, it said on Monday, ...
AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...
The pharma is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer and ...
The transaction is expected to close in the second quarter of 2025, which will include AstraZeneca will buying all ...
GlobalData on MSN2d
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase IIIUK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic hypoparathyroidism. The Calypso trial (NCT05778071) of eneboparatide, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback